After initiating a wind-down more than 18 months ago and exploring liquidation, Galera Therapeutics has found a partner via a reverse merger with Obsidian Therapeutics that will take oncology-focused Obsidian public.
Astellas is preparing to close its Seattle site for its stem cell therapy unit, with around 55 employees set to be affected.
Takeda has pulled back from a research collaboration with a fellow Japanese life sciences company, ending work to discover new small molecules that target mRNA.
Kazia Therapeutics is paying $1.4 million upfront to secure a platform for generating epigenetic drugs from an Australian research institute.
Eli Lilly has turned its attention down south with a $300 million biobuck acquisition of Houston-based CrossBridge Bio, aiming to advance its dual-payload antibody-drug conjugate (ADCs) pipeline.
An FDA review of records found that results have not been reported for 30% of registered clinical studies. To remedy this shortfall, the U.S. regulator has sent reminders to 2,200 drug companies, medical device manufacturers and researchers urging them to report their results.
Kailera is taking another step into the competitive obesity market by aiming to raise up to $528.5 million via a Nasdaq IPO, with proceeds intended to advance its GLP-1 assets through clinical development.
Spyre Therapeutics’ monoclonal antibody hit the key goal of a phase 2 study in ulcerative colitis, which the company has touted as proof it can best Takeda’s Entyvio.
AbbVie has agreed to pay $30 million upfront to Chinese biotech Haisco Pharmaceutical Group for two non-opioid pain treatment candidates.
A phase 2/3 trial of Ideaya Biosciences and Servier’s eye cancer candidate has hit its primary endpoint, teeing up a filing for accelerated FDA approval in the second half of the year.
